

Table S1. P value of univariate analysis in B-other ALL patients

| Variable | RFS | OS |
|--|--------|--------|
| <i>ZNF384</i> fusions (Yes vs No) | 0.021 | 0.13 |
| Sex (M vs F) | 0.32 | 0.46 |
| Hemoglobin (g/L) (≤ 90 vs > 90) | 0.87 | 0.25 |
| Platelet count ($\times 10^9/L$) (≥ 60 vs < 60) | 0.0030 | 0.13 |
| Risk (low vs high) (n=224) | 0.060 | 0.023 |
| IKZF1 deletion (Yes vs No)(n=116) | 0.77 | 0.43 |
| Treatment modality (allo-HSCT vs chemotherapy alone) | <0.001 | <0.001 |
| Achieving CR within 4 weeks (Yes vs No) | 0.0010 | <0.001 |
| MRD>0.01% at remission (No vs Yes) (n=175) | 0.6200 | 0.72 |
| MRD>0.01% after 1st consolidation (No vs Yes) (n=167) | 0.46 | 0.98 |

Table S2. Multivariate analysis of RFS and OS in B-other ALL patients

| Variable | RFS | | OS | |
|--|---------------|---------|----------------|---------|
| | HR (95% CI) | P value | HR (95% CI) | P value |
| <i>ZNF384</i> fusions (Yes vs No) | - | 0.64 | - | 0.69 |
| Platelet count ($\times 10^9/L$) (≥ 60 vs < 60) | 1.9 (1.2-3.2) | 0.011 | - | 0.68 |
| Risk (low vs high) | - | 0.49 | - | 0.39 |
| Treatment modality (allo-HSCT vs chemotherapy alone) | 6.6 | <0.001 | 5.0 (3.0-8.5) | <0.001 |
| Achieving CR within 4 weeks (Yes vs No) | 3.8 (1.6-9.0) | 0.0030 | 7.5 (4.1-13.4) | <0.001 |

Figure legends

Figure S1. The impact of *ZNF384* fusions on RFS and OS considering treatment modality. (A) RFS of patients receiving chemotherapy alone. (B) OS of patients receiving chemotherapy alone. (C) RFS of patients who received allo-HSCT were censored at the time of transplantation. (D) OS of patients who received allo-HSCT were censored at the time of transplantation. (E) RFS of patients receiving allo-HSCT. (F) OS of patients receiving allo-HSCT.

Figure S2. Comparison of RFS and OS among subtypes in patients receiving chemotherapy alone. (A) RFS. (B) OS.